Bitter Melon
7 benefits mapped to clinical evidence across supplements.
Dose per serving from products
190 products in our catalogue print how much Bitter Melon a serving holds.
Most common: 25 mg to 50 mg and 50 mg to 100 mg, 22% of 190 products each.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 10 |
| 10 mg to 25 mg | 23 |
| 25 mg to 50 mg | 42 |
| 50 mg to 100 mg | 42 |
| 100 mg to 250 mg | 32 |
| 250 mg to 500 mg | 24 |
| 500 mg to 1 g | 9 |
| over 1 g | 8 |
Dose per serving from research
10 study groups in 7 studies say how much Bitter Melon participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 60% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 1 |
| 1 g to 2.5 g | 6 |
| 2.5 g to 5 g | 2 |
Benefit Evidence
Research sources
Blood sugar (6)
- The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial
PubMed ID: 30057048
Knee OA trial reported reduced fasting glucose in bitter melon group—supports glycemic benefit in a clinical setting.
- Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes
PubMed ID: 39536276
12‑week prediabetes trial blunted increases in fasting glucose versus control—protective glycemic effect.
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
PubMed ID: 25623883
10‑week RCT showed clinically meaningful reductions in HbA1c and fasting glucose versus baseline/placebo.
- Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population
PubMed ID: 40199408
Controlled trials (incl. 12‑week) reported reductions in fasting glucose, fasting insulin and HOMA‑IR in prediabetics.
- Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania
PubMed ID: 29339109
8‑week crossover in prediabetics lowered fasting glucose by ~5.6 mg/dL—significant glycemic effect.
- Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
PubMed ID: 32951763
12‑week RCT lowered fasting glucose (but not HbA1c)—modest glycemic benefit.
Metabolism (5)
- Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population
PubMed ID: 40199408
Controlled trials showing improved FPG, fasting insulin and HOMA‑IR in prediabetics provide robust metabolic support.
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
PubMed ID: 25623883
Randomized trial showed improvements in HbA1c, fasting glucose and triglycerides—strong metabolic evidence.
- Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania
PubMed ID: 29339109
Prediabetes crossover trial lowered fasting glucose—meaningful metabolic impact.
- Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
PubMed ID: 32951763
12‑week RCT lowered fasting glucose though HbA1c unchanged—moderate metabolic support.
- Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes
PubMed ID: 39536276
Blunted fasting glucose increase in prediabetics suggests protective metabolic action.
Wellbeing (2)
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
PubMed ID: 25623883
Broad metabolic improvements (HbA1c, FPG, TG) in a randomized trial suggest general wellness benefits.
- Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population
PubMed ID: 40199408
Controlled trials showing improvements in FPG, insulin and HOMA‑IR support broader metabolic wellness.
Cholesterol (1)
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
PubMed ID: 25623883
10‑week RCT reduced triglycerides (though other cholesterol fractions less clear)—supports healthier lipid profile.
Heart health (1)
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
PubMed ID: 25623883
Reduced triglycerides in 10-week RCT—favors cardiovascular risk profile.
Inflammation (1)
- The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial
PubMed ID: 30057048
Improved pain and reduced analgesic use in osteoarthritis suggest possible anti‑inflammatory or analgesic effects.
Weight management (1)
- The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial
PubMed ID: 30057048
3‑month trial in knee OA reported modest weight reduction in bitter melon group.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Bitter Melon
Search all426 products whose verified label declares Bitter Melon — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.